|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 五个月短程化疗及六个月全程间歇方案治疗菌阳肺结核的临床对照研究显示文摘目的考核利福喷丁(L)的疗效;缩短疗程或全程间歇以减少用药次数;观察全程应用吡嗪酰胺(Z)对疗效及毒副反应的影响。方法以利福平(R)为对照,采用5个月疗程方案(Ⅰ组2SHRZ/3R2H2Z2,Ⅱ组2SHRZ/3L1H2Z2)、6个月全间歇方案(Ⅲ组2S3H3R3Z3/4L1H2Z2,Ⅳ组2S3H3R3Z3/4L1H2E2),观察Z的全程应用结果,巩固期以乙胺丁醇(E)为对照。366例初治菌阳肺结核随机分入以上4组。结果(1)339例完成疗程者中329例治疗成功,满疗程时痰菌阴转率Ⅰ~Ⅳ组分别为970%、941%、1000%、972%。X线病灶有效率依序为960%、976%、1000%和944%。5个月组与6个月组空洞关闭率分别为77%及76%。各组相互比较均无显著性差异(P>0.05),未见严重副作用。(2)305例完成3年随访,Ⅰ、Ⅱ、Ⅲ、Ⅳ组细菌学加X线复发分别为2、3、6和3例。结论本研究结果进一步证明L是长效、高效、安全、便于督导的新药;巩固期用Z无必要;现有基本药物合理联用有可能缩短疗程为5个月,值得进一步研究。 | National Cooperative Group On Clinical Study of Pulmonary Tuberculosis (Report prepared by Chu Naihui , Yan Biya, Zhu Lizhen). Beijing Tuberculosis and Thoracic Tumor Institute, Beijing 101149 | 1998 | 中华结核和呼吸杂志1998，21，7： | 26 |
| 2 | Transforming growth factor-β1 gene polymorphisms associated with chronic obstructive pulmonary disease in Chinese population显示文摘Aim: To determine the frequencies of polymorphism and haplotype in the transforming growth factor-beta 1 (TGF-β1) gene promoter in the Chinese population and to investigate the susceptibility of this population to chronic obstructive pulmonary disease (COPD). Methods: The target fragments of the TGF-β1 gene promoter were amplified and analyzed by polymerase chain reaction-restriction fragment length polymorphism technique in 84 COPD patients and 97 age-and sex-matched healthy controls. The test for Hardy-Weinberg equilibrium was performed using HWE program of the LINKUTIL package and statistical analysis was carded out with the SPSS statistical package. An expectation maximization algorithm was used for the pairwise linkage disequilibrium test and haplotype analysis. Results: More carriers of the -800A allele, or fewer carders of the -509T allele, were detected in the COPD patients compared with the non-symptomatic control subjects [for the -800A allele, 29.8% vs 14.4%, respectively, χ^2=6.257,degrees of freedom (df)=l, P=0.012; for the-509T allele, 27.3% vs 44.3%, respectively, χ^2=5.582, df=1, P=0.018]. The prevalence of the-800A allele was significantly higher in the COPD patients than in control subjects (P=0.009), whereas the frequency of the-509T allele was significantly higher in control subjects than in the COPD patients (P=0.008). In addition, this distribution tendency for the-800A or-509T allele was similar in heavy smokers (smoking history≥20 pack years);(number of packs of cigarettes per day multiplied by the number of years of smoking)χ^2=7.235, P=0.007, and χ^2=5.636, P=0.018, respectively). The linkage disequilibrium was found between-800 G→A and-509 C→T (D>0.60, P<0.0001), and the frequency of the AC haplotype, consisting of the least common base at -800 and the most common base at -509, was significantly higher in patients with COPD than in controls (0.056 vs 0.021, P<0.05). Conclusions: The single nucleotide polymorphism (SNP) in the TGF-β1 gene promoter might be associated with COPD,and the -800A/-509C haplotype is possibly one of the susceptibility factors for COPD. | Zhi-guang SU~2, Fu-qiang WEN, Yu-lin FENG, Min XIAO, Xiao-ling WU Laboratory of Pulmonary Medicine, West China Hospital, Sichuan University Key Laboratory of Biotherapy of Human Disease, Ministry of Education, Chengdu 610041, China | 2005 | Acta Pharmacologica Sinica2005，26，6： | 17 |
| 3 | Microarray,SAGE and their applications to cardiovascular diseases显示文摘The wealth of DNA data generated by the human genome project coupling with recently invented high-throughput gene expression profiling techniques has dramatically sped up the process for biomedical researchers on elucidating the role of genes in human diseases. One powerful method to reveal insight into gene functions is the systematic analysis of gene expression. Two popular high-throughput gene expression technologies, microarray and Serial Analysis of Gene Expression (SAGE) are capable of producing large amounts of gene expression data with the potential of providing novel insights into fundamental disease processes, especially complex syndromes such as cardiovascular disease, whose etiologies are due to multiple genetic factors and their interplay with the environment. Microarray and SAGE have already been used to examine gene expression patterns of cell-culture, animal and human tissues models of cardiovascular diseases. In this review, we will first give a brief introduction of microarray and SAGE technologies and point out their limitations. We will then discuss the major discoveries and the new biological insightsthat have emerged from their applications to cardiovascular diseases. Finally we will touch upon potential challenges and future developments in this area. | SHUI QING YE, TERA LAVOIE, DAVID C USHER, LI Q. ZHANG1 Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21224, USA2Department of Biological Science, University of Delaware, Newark, DE 19716, USA | 2002 | Cell Research2002，12，2： | 5 |
| 4 | , a randomized controlled trial 显示文摘 | Keenan SP Powers CE McCormack DG Noninvasive positive- pressure ventilation in patients with milder chronic obstructive pulmonary disease exacerbations | 2005 | RespirCare2005，50，5： | 1 |
| 5 | British Thoracic Society guide- lines for the management of suspected acute pulmonary embolism 显示文摘 | British Thoracic Society Standards of Care Committee Pulmonary Em- bolism Guideline Development Group | 2003 | Thorax2003，58，： | 1 |
| 6 | ATS statement : guidelines for the six- minute walk test显示文摘 | ATS Committee on Proficiency Standards for Clinical Pulmonary Func- tion Laboratories | 2002 | American journal of respiratory and critical care medicine2002，166，1： | 1 |
| 7 | British Thoracic Society guidelines for the management of suspected acute pulmonary embolism显示文摘 | British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group | 2003 | Thorax2003，58，： | 1 |
| 8 | Guidelines on diagnosis and management of acute pulmonary embolism显示文摘 | Task Force on Pulmonary Embolism European Society of Cardiology | 2000 | Eur Heart J2000，21，16： | 1 |
| 9 | Prednisone, azathioprine, and N - acetylcysteine forpul- monary fibrosis显示文摘 | Idiopathic Pulmonary Fibrosis Clinical Research Network Raghu G Anstrom KJ | 2012 | N Engl J Med2012，366，21： | 1 |
| 10 | Global strategy for the management, and prevention of chronic obstructive disease: GOLD executive summary显示文摘 | Vestbo J diagnosis pulmonary Care Med Hurd S S Agusti A G | 2012 | Am J Respir Crit2012，92，14： | 1 |
| 11 | ATS statement : guidelines for the six-minute walk test显示文摘 | ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories | 2002 | Am J Respir Crit Care Med2002，166，1： | 1 |
| 12 | The sixth(2000)guidelines for antithrombotic therapy for prevention and treatment of thrombosis显示文摘 | ACCP consensus committe on pulmonary embolism | 2001 | Chest2001，119，： | 1 |
| 13 | ATS statement: guidelines for the six - mi- nute walk test显示文摘 | ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories | 2002 | Am J Respir Crit Care Med2002，166，1： | 1 |
| 14 | ATS statement:guidelines for the six minute walktest显示文摘 | ATS Conunittee on Profieieney Standards for Clinieal Pulmonary Funetion Laboratories | 2002 | Am J Respir Crit Care Med2002，166，1： | 1 |
| 15 | British Thoracic Society guidelines for the management of suspected acute pulmonary embolism显示文摘 | British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group | 2003 | Thorax2003，58，6： | 1 |
| 16 | Molecularas determined by microdissection-based allelotyping 显示文摘 | Dacic S Finkelstein S D pathogenesis of pulmonary Sasatomi E | 2002 | Am J Surg Pathol2002，26，4： | 1 |
| 17 | ATS statement : guidelines for the six-minutewalk test 显示文摘 | ATS Committee on Proficiency Standards for Clinical Pulmonary Fu-nction Laboratories | 2002 | Am J Respir Crit Care Med2002，166，1： | 1 |
| 18 | ATS statement : guidelines for the six - minute walk test显示文摘 | ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories | 2002 | Am J Respir Crit Care Meal2002，166，1： | 1 |
| 19 | ATS statement:guidelines for the six--minute walk test 显示文摘 | ATS Committee on Proficiency standards for Clinical Pulmonary Function Laboratories | 2002 | Am J Respir Crit Care Med2002，166，： | 1 |
| 20 | ATS statement: guidelines for the six- minute walk test 显示文摘 | ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories | 2002 | Am J Respir Crit Care Med2002，166，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员